Clinical trials: Benign Hyperplasia of Prostate
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH
The ProArc Medical Omega system is a prostatic reshaping device that is designed to treat Lower Urinary Tract Symptoms (LUTS) due to BPH.
- Trial name
- NCT04627701
- Testing
- Omega
- Where
- 4 sites in Israel, New Zealand
- Volunteers
- 26 people
- Sponsor
- ProArc Medical
Benign Prostatic Hyperplasia (BPH)
Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)
The HistoSonics' Histotripsy BPH Device, the Vortx Rx, is a portable ultrasound therapy device. The purpose of this study is to assess and monitor the performance of the Vortx Rx for initial safety and efficacy for the treatment…
- Trial name
- NCT01896973
- Testing
- Vortx Rx - Histotripsy BPH Device
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- HistoSonics, Inc.
BPH Without Urinary Obstruction and Other Lower Urinary Tract Symptoms (LUTS)
The Effect of BRIZO on Lower Urinary Tract Symptoms (LUTS) Related to Benign Prostatic Hypertrophy (BPH)
A randomized, placebo controlled double-blind, 12-week treatment trial in men with moderate to severe symptoms of benign prostatic hyperplasia.
- Trial name
- NCT05227508
- Testing
- BRIZO
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Se-cure Pharmaceuticals Ltd.
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Butterfly Pivotal Study
A prospective, multicenter, blind randomized (2:1) controlled study comparing the International Prostate Symptom Score (IPSS) of the Active arm to the IPSS of the control arm at the 3 months follow-up and active arm IPSS score…
- Trial name
- NCT05341661
- Testing
- Butterfly Prostatic Retraction Device
- Where
- 3 sites in United States
- Volunteers
- 245 people
- Sponsor
- Butterfly Medical Ltd.
Prostatic Hyperplasia
WEUSKOP5723: Prostate Cancer Study
This retrospective cohort study will assess the association of benign prostatic hyperplasia (BPH) treatment (5-alpha reductase inhibitors (5ARI) and alpha-blocker medications) with the occurrence of prostate cancer related…
- Trial name
- NCT01767363
- Testing
- 5-alpha reductase inhibitors, Alpha-blockers
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Nocturia, Benign Prostatic Hypertrophy (BPH)
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
The purpose of this study is to establish the dose response relationship of VA106483 and nocturnal urine volumes in a population of elderly male subjects with Benign Prostatic Hypertrophy (BPH) who are likely to present with…
- Trial name
- NCT01330927
- Testing
- VA106483
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Vantia Ltd
Benign Prostatic Hyperplasia
RELIEF Study: Real-world Evaluation of LUTS Interventions and Patient Experience During Follow-up
The objective of the RELIEF Study is to compare the safety, effectiveness and patient experience outcomes in real-world subjects treated with different modalities for symptomatic BPH.
- Trial name
- RELIEF (NCT05784558)
- Testing
- UroLift System, Watchful Waiting or BPH Medications, Other Surgical Intervention
- Where
- United States
- Sponsor
- NeoTract, Inc.
Prostatic Hyperplasia
Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)
Study to assess efficacy, tolerability and safety parameters of a one month ALNA® - treatment after switch from Terazosin-treatment
- Trial name
- NCT02244333
- Testing
- ALNA®
- Volunteers
- 4,575 people
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia, Acute Urinary Retention
ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH
To assess the efficacy of alfuzosin 10mg OD in the management of acute urinary retention associated with BPH. To assess the safety of alfuzosin in this population and health care consumption.
- Trial name
- NCT00290030
- Testing
- Alfuzosin
- Volunteers
- 800 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH
A new drug for the treatment of benign prostatic hyperplasia is compared with placebo and tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe and effective (the first phase of the study…
- Trial name
- NCT00359905
- Testing
- Silodosin, Tamsulosin
- Where
- United Kingdom
- Volunteers
- 1,228 people
- Sponsor
- RECORDATI GROUP
Benign Prostatic Hyperplasia
Safety and Feasibility of the XFLO Expander System (Mercury)
To demonstrate the safety and feasibility of the Mercury Expander system and procedure to treat patients with lower urinary tract symptoms (LUTS) secondary to urinary outflow obstruction from benign prostatic hyperplasia.
- Trial name
- EXPANDER-1 (NCT03758222)
- Testing
- XFLO Expander System
- Where
- 5 sites in Australia, Canada and 2 more
- Volunteers
- 45 people
- Sponsor
- MedeonBio, Inc.
Benign Prostatic Hyperplasia (BPH)
Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered as a treatment for Benign prostate hyperplasia(BPH).
- Trial name
- NCT04032067
- Where
- 23 sites in South Korea
- Volunteers
- 423 people
- Sponsor
- GemVax & Kael
Benign Prostatic Hyperplasia
Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II
A single-arm prospective, interventional clinical trial to evaluate the safety and performance of obtaining hemostasis following prostate resection using the AQUABEAM for treatment of LUTS resulting from BPH.
- Trial name
- AHA II (NCT03125889)
- Testing
- AquaBeam System
- Where
- India
- Volunteers
- 11 people
- Sponsor
- PROCEPT BioRobotics
Overactive Bladder
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
- Trial name
- NCT02656173
- Testing
- Mirabegron, Tamsulosin
- Where
- 58 sites in Japan, South Korea
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Inc
Prostatic Hyperplasia, Benign Prostatic Hyperplasia
Rezum I Pilot Study for Benign Prostatic Hyperplasia
Evaluate the safety and efficacy of the Rezum System for the treatment of BPH
- Conditions
- Prostatic Hyperplasia, Benign Prostatic Hyperplasia, Adenoma, Prostatic, Prostatic Adenoma
- Trial name
- Rezum Pilot (NCT02943070)
- Testing
- Rezum System
- Where
- 3 sites in Czechia, Dominican Republic and 1 more
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia
The purpose of this study is to confirm in a larger population in Europe the effectiveness and safety observed with silodosin in previous clinical trials.
- Trial name
- SiRE (NCT01757769)
- Testing
- Silodosin
- Where
- Italy
- Volunteers
- 1,036 people
- Sponsor
- RECORDATI GROUP
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension
This study is a randomized, double-blind, placebo-controlled, parallel-design to compare the efficacy and safety of tadalafil once-a-day dosing versus placebo for 12 weeks followed by an open-label extension to evaluate the…
- Trial name
- NCT00783094
- Testing
- Tadalafil 2.5 mg, Tadalafil 5 mg
- Where
- 6 sites in Japan
- Volunteers
- 422 people
- Sponsor
- Eli Lilly and Company
Overactive Bladder, Urinary Urgency Incontinence
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
- Conditions
- Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer
- Trial name
- NCT06511141
- Testing
- Axonics SNM System
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- Axonics, Inc.
Benign Prostatic Hyperplasia
A Prospective, Multicenter, Open-label Study of the Beacon Platform for Holmium Laser Enucleation of the Prostate (HoLEP)
Robotic assisted surgery for benign prostatic hyperplasia (BPH)
- Trial name
- NCT06668142
- Testing
- Beacon Platform
- Where
- 3 sites in Chile, New Zealand
- Volunteers
- 54 people
- Sponsor
- Andromeda Surgical
Benign Prostatic Hyperplasia
GreenLight XPS Laser System Retrospective Chart Review
The purpose of this study is to gain information on the safety, efficacy, and quality of life in subjects who have had the GreenLight XPS procedure.
- Trial name
- NCT02139969
- Testing
- GreenLight XPS Laser System
- Where
- 6 sites in United States, Canada
- Volunteers
- 956 people
- Sponsor
- Boston Scientific Corporation